GLENN Gilbert has been appointed as CEO and Managing Director of Signature Oncology Pty Ltd effective 09 Jun.
Founded last year, Signature is a cancer diagnostics platform company focused on the development of unique gene signature assays to empower clinician decision-making to advance patient care.
Commencing yesterday, Gilbert will act as an exclusive consultant to Signature while the company completes a capital raise to fund the next development phase of its proprietary gene signature melanoma diagnostic.
Following the completion of the capital raise, Gilbert will then assume his new role.
Gilbert explained that "40-50% of advanced melanoma patients are unresponsive to checkpoint inhibitors, otherwise known as immunotherapy drugs.
"There is a significant market opportunity for our proprietary diagnostic test to guide clinician decision-making, reduce healthcare costs and prevent patient exposure to unnecessary and unpleasant side-effects.
"In addition, those pharmaceutical companies with novel checkpoint inhibitors looking to select responders in clinical trials and become a standard treatment in the emerging neoadjuvant melanoma setting could also benefit from our novel diagnostic."
Gilbert has over 18 years of experience in the healthcare sector (including pharmaceutical, medical device (Rx and OTC) and IVD industries) across domestic and international markets.
He was the former CEO and Managing Director at Rhythm Biosciences, and during his tenure, grew the market capitalisation from circa $3m in Mar 2020 to a peak of circa $400m.
Before Rhythm, Gilbert held leadership roles at CSL and Medical Developments International, and has extensive business experience across the UK, Europe, Asia, and North and South America.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 23
